Speciality: Oncology
Description:
Welcome to an insightful discussion on the critical topic of Cost Burden and Burden of Hospitalization for Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL) Patients. Esteemed experts Dr. Pawan Kumar Singh, Dr. Roshan Dikshit, Dr. Manisha Jain, and Dr. Avriti Baveja delve into the multifaceted challenges faced by patients and healthcare systems. The conversation sheds light on the financial, emotional, and logistical strains of prolonged hospitalization, recurring treatments, and the socioeconomic disparities impacting access to advanced therapies. This session is a must-watch for healthcare professionals, policymakers, and caregivers seeking to understand the real-world implications of managing R/R ALL.
In the second segment, the panel explores actionable strategies to alleviate the burden on patients and families. Dr. Singh emphasizes the importance of cost-effective treatment protocols, while Dr. Dikshit highlights innovations in outpatient care models to reduce hospitalization frequency. Dr. Jain and Dr. Baveja further discuss the role of patient advocacy, insurance reforms, and government policies in bridging gaps in care. Their collective expertise provides a comprehensive roadmap to address systemic inefficiencies and improve the quality of life for R/R ALL patients.
Concluding on a hopeful note, the experts underscore the need for collaborative efforts between clinicians, researchers, and policymakers to drive sustainable change. The discussion not only raises awareness but also inspires actionable solutions to mitigate the economic and emotional toll of R/R ALL. Viewers are encouraged to watch the full video to gain deeper insights into this pressing issue and stay tuned for future discussions featuring these thought leaders in oncology and hematology.
See More Webinars @ Hidoc Webinars
1.
Inner Thoughts of Leonard Bernstein, the "Maestro".
2.
Mobile prostate cancer screening clinic can ID the disease in disadvantaged men
3.
No Survival Benefit Seen With Adjuvant Atezolizumab in TNBC
4.
Parents, teachers at Missouri school want answers after string of cancer diagnoses
5.
A promising medication could slow brain tumors in children.
1.
Future-Ready Cancer Screening: What Every Clinician Should Know in 2025
2.
Cancer Evolution and Therapeutic Resistance: Mechanisms, Clinical Insights, and Emerging Strategies
3.
Targeting Cancer Stem Cells in Solid Tumors: Mechanisms, Clinical Implications, and Therapeutic Advances
4.
Partial Gland Ablation in Prostate Cancer: Oncologic Outcomes in Intermediate-Risk Cases
5.
Generative AI for Adaptive Oncology Trial Design
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part III
2.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part I
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC
4.
INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients
5.
Current Scenario of Cancer- The Incidence of Cancer in Men
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation